Patent details

EP2303917 Title: ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS

Basic Information

Publication number:
EP2303917
PCT Application Number:
US2009003808
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP097705537
PCT Publication Number:
WO2009158015
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS
French Title of Invention:
ANTAGONISTES D'ACTRIIB ET UTILISATIONS POUR AUGMENTER LES TAUX 
D'ÉRYTHROCYTES
German Title of Invention:
ANTAGONISTEN VON ACTRIIB UND ANWENDUNGEN ZUR ERHÖHUNG DER KONZENTRATION AN ROTEN BLUTKÖRPERCHEN
SPC Number:

Dates

Filing date:
26/06/2009
Grant date:
11/11/2020
EP Publication Date:
06/04/1900
PCT Publication Date:
30/12/2009
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
11/11/2020
EP B1 Publication Date:
26/10/2016
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
26/06/2021
Expiration date:
26/06/2029
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
31/07/2019
 
 

Name:
Acceleron Pharma Inc.
Address:
128 Sidney Street, Cambridge, MA 02139, United States (US)

Inventor

1

Name:
BORGSTEIN, Niels
Address:
United States (US)

2

Name:
SHERMAN, Matthew, L.
Address:
United States (US)

3

Name:
SEEHRA, Jasbir
Address:
United States (US)

Priority

Priority Number:
133368 P
Priority Date:
26/06/2008
Priority Country:
United States (US)

Classification

IPC classification:
A61K 38/17; A61P 7/06; A61K 47/68;

Publication

European Patent Bulletin

Issue number:
202046
Publication date:
20/12/2013
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages